Prana's PBT2 Featured as a Top 10 Global Neuroscience Project
November 19 2013 - 9:00AM
Marketwired
Prana's PBT2 Featured as a Top 10 Global Neuroscience Project
MELBOURNE, AUSTRALIA--(Marketwired - Nov 19, 2013) - Prana
Biotechnology (NASDAQ: PRAN) (ASX: PBT), a leading innovative drug
developer targeting disease modification in neurodegenerative
diseases announced today that the Company will present at The 2013
Therapeutic Area Partnerships (TAP) meeting in Boston,
Massachusetts. Since launching eight years ago by Elsevier,
TAP has come to be regarded as the industry's premier
biopharmaceutical partnering event.
Dr. Peter Smith, Prana's VP Business Development, is presenting
at 11:50 AM EST on Tuesday, November 19, 2013.
Elsevier Business Intelligence named clinical drug PBT2 as one
of the Top 10 Neuroscience Projects to Watch earlier this year,
following its selection by an independent panel. Each year a
list is compiled to highlight compounds which address a large,
unmet market, strong science and a diversity of indications.
PBT2 is a novel, best-in-class agent under development for
Huntington's and Alzheimer's diseases with Phase 2 clinical trial
results due for both in the first quarter of 2014.
About Prana Biotechnology Limited Prana Biotechnology was
established to commercialise research into age-related
neurodegenerative disorders. The Company was incorporated in 1997
and listed on the Australian Securities Exchange in March 2000 and
listed on NASDAQ in September 2002. Researchers at prominent
international institutions including The University of Melbourne,
The Mental Health Research Institute (Melbourne) and Massachusetts
General Hospital, a teaching hospital of Harvard Medical School,
contributed to the discovery of Prana's technology.
For further information please visit the Company's web site at
www.pranabio.com.
Forward Looking Statements
This press release contains "forward-looking statements"
within the meaning of section 27A of the Securities Act of 1933 and
section 21E of the Securities Exchange Act of 1934. The
Company has tried to identify such forward-looking statements by
use of such words as "expects," "intends," "hopes," "anticipates,"
"believes," "could," "may," "evidences" and "estimates," and other
similar expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are
not limited to any statements relating to the Company's drug
development program, including, but not limited to the initiation,
progress and outcomes of clinical trials of the Company's drug
development program, including, but not limited to, PBT2, and any
other statements that are not historical facts. Such
statements involve risks and uncertainties, including, but not
limited to, those risks and uncertainties relating to the
difficulties or delays in financing, development, testing,
regulatory approval, production and marketing of the Company's drug
components, including, but not limited to, PBT2, the ability of the
Company to procure additional future sources of financing,
unexpected adverse side effects or inadequate therapeutic efficacy
of the Company's drug compounds, including, but not limited to,
PBT2, that could slow or prevent products coming to market, the
uncertainty of patent protection for the Company's intellectual
property or trade secrets, including, but not limited to, the
intellectual property relating to PBT2, and other risks
detailed from time to time in the filings the Company makes with
Securities and Exchange Commission including its annual reports on
Form 20-F and its reports on Form 6-K. Such statements are
based on management's current expectations, but actual results may
differ materially due to various factions including those risks and
uncertainties mentioned or referred to in this press
release. Accordingly, you should not rely on those
forward-looking statements as a prediction of actual future
results.
Contacts: USA: Vivian Chen Grayling T: +1 646-284-9472
Vivian.Chen@grayling.com Australia: Investor Relations Rebecca
Wilson T: +61 3 8866 1216 E: rwilson@buchanwe.com.au Media
Relations Ben Oliver T: +61 3 8866 1233 E:
boliver@buchanwe.com.au
Prana Biotechnology Ltd ADS (NASDAQ:PRAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prana Biotechnology Ltd ADS (NASDAQ:PRAN)
Historical Stock Chart
From Apr 2023 to Apr 2024